Toward an Optimal Global Stem Cell Donor Recruitment Strategy

Alexander H. Schmidt¹*, Jürgen Sauter¹*, Julia Pingel¹, Gerhard Ehninger²

¹ DKMS German Bone Marrow Donor Center, Tübingen, Germany, ² Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

Abstract

Population-specific matching probabilities (MP) are a key parameter to assess the benefits of unrelated stem cell donor registries and the need for further donor recruitment efforts. In this study, we describe a general framework for MP estimations of specific and mixed patient populations under consideration of international stem cell donor exchange. Calculations were based on population-specific 4-locus (HLA-A, -B, -C, -DRB1) high-resolution haplotype frequencies (HF) of up to 21 populations. In various scenarios, we calculated several quantities of high practical relevance, including the maximal MP that can be reached by recruiting a fixed number of donors, the corresponding optimal composition by population of new registrants, and the minimal number of donors who need to be recruited to reach a defined MP. Starting at current donor numbers, the largest MP increases due to \( n = 500,000 \) additional same-population donors were observed for patients from Bosnia-Herzegovina (\( +0.25 \)), Greece (\( +0.21 \)) and Romania (\( +0.20 \)). Especially small MP increases occurred for European Americans (\( +0.004 \)), Germans (\( +0.01 \)) and Hispanic Americans (\( +0.01 \)). Due to the large Chinese population, the optimal distribution of \( n = 5,000,000 \) new donors worldwide included 3.9 million Chinese donors. As a general result of our calculations, we observed a need for same-population donor recruitment in order to increase population-specific MP efficiently. This result was robust despite limitations of our input data, including the use of HF derived from relatively small samples ranging from \( n = 1028 \) (Bosnia-Herzegovina) to \( n = 33,083 \) (Turkey) individuals. National strategies that neglect domestic donor recruitment should therefore be critically re-assessed, especially if only few donors have been recruited so far.

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is an increasingly used therapy for leukemia and other severe blood diseases [1,2]. Unrelated donor searches are carried out for patients without human leukocyte antigen (HLA)-identical siblings. Due to the extensive diversity of the HLA system and the need for exact donor-recipient HLA matching, large unrelated donor registries have been established. As of June 2013, there were more than 21.1 million potential stem cell donors in 69 registries from 50 countries [3]. 14,209 unrelated stem cell donations were from 50 countries [3]. 14,209 unrelated stem cell donations were reported to the World Marrow Donor Association in 2011. Of these donations, 6,513 (45.8%) were cross-border [4].

The probability to find at least one HLA-matched donor for a patient from a specific population in a defined donor file is a key parameter in strategic donor registry planning. The definition of an HLA-matched donor has changed over time. Currently, a donor who matches with at least for the HLA loci A, B, C and DRB1 at high resolution (“8/8 high-resolution matching”) is regarded as HLA-matched [5–9]. For high-resolution typing, all alleles are resolved within the antigen recognition site. This requires sequencing of exons 2 and 3 for class I genes (HLA-A, -B, and -C) and exon 2 for HLA-DRB1. Contrary to the one-step sequencing strategy proposed by Tu et al. [10], cis-trans ambiguities within the relevant exons are resolved while synonymous mutations inside or outside the relevant exons are not taken into account. Allele ambiguities from non-synonymous mutations outside the relevant exons are also not resolved.

Methods for the calculation of matching probabilities (MP) by donor file size have been developed since the 1980s [11,12] and are well established [13–15]. They are based on population-specific HLA haplotype frequencies (HF) that can be estimated from phenotypic data using appropriate tools as the expectation-maximization algorithm [16,17].

Many MP analyses restrict to one or two populations, i.e., they consider one donor population and one patient population that may be identical or not. Given the considerable amount of international exchange of stem cell products, these models seem to be oversimplifying. MP for specific patient populations that consider donors from various populations have been derived by Dehn et al. [18]. Due to the empirical nature of that study, an extrapolation of the results to larger donor file sizes is difficult. In a previous study, we used simulation techniques to estimate MP of Polish patients for varying sizes of a combined Polish-German donor file [19]. Here, we describe a general framework for MP estimations of specific or combined patient populations in a model including international stem cell donor exchange. We apply our
framework to real data for up to 21 populations. Practical applications of this approach have come into reach as population-specific high-resolution 4-locus HF are increasingly available.

Methods

Calculation of Matching Probabilities

The probability \( p(n) \) for a random patient from a given population to find at least one matching donor in a registry including \( n \) individuals of a donor population is given by

\[
p(n) = 1 - \prod_{i=1}^{M} f_i (1 - g_i)^n
\]

with \( f_i \) and \( g_i \) being the frequencies of the \( i \)-th phenotype in the patient and donor populations, respectively. Here and in the following, \( M \) is the number of different phenotypes. Phenotype frequencies are derived from known HF under the assumption of Hardy-Weinberg equilibrium (HWE). Throughout this paper, we analyze 8/8 high-resolution matching. The phenotypes considered are, therefore, HLA-A, -B, -C, -DRB1 high-resolution phenotypes. All methods used would also be applicable to donor-recipient matching based on different genes or typing resolutions.

It has been shown [20] that the probability \( p_k \) to find at least one matching donor for a patient of population \( k \) in a registry including donors from \( N \) populations is given by

\[
p_k(n_1, n_2, \ldots, n_N) = 1 - \prod_{j=1}^{N} f_j \Pi_{i=1}^{M} (1 - f_{ij})^{n_j}
\]

where \( n_j \) indicates the number of donors from population \( j \) in the registry and the frequency of the \( i \)-th phenotype in population \( j \) is denoted by \( f_{ij} \). The probability \( p_k \) describes a scalar field over the \( N \)-dimensional space \( U_N \) of population-specific donor numbers. Mathematical properties of this scalar field are described in File S1.

In order to assess global benefits of a donor registry, it is also necessary to estimate \( MP \) for a combined patient population. If \( m_k \) describes the fraction of patients of population \( k \) with donor searches in a defined time interval then \( p(n_1, n_2, \ldots, n_N) = \sum_{k=1}^{N} m_k p_k(n_1, n_2, \ldots, n_N) \) describes the MP for the combined patient population. For our example calculations, we assumed the numbers of patients with donor searches were proportional to population sizes.

Optimization of Matching Probabilities

We analyzed two optimization scenarios: First, we determined the optimal composition of new donors and resulting maximum values of population-specific and combined MP under the assumption that a fixed number of new donors is added to a donor registry characterized by population-specific donor numbers and HF. Second, we determined minimum numbers of new donors who need to be added to the current registry in order to increase certain MP to defined targets as, for example, \( p_2 = 0.8 \). Mathematical details of the algorithm are given in the File S2.

Input Data for Model Calculations

All HF data processed in this work were calculated from samples with size \( n \geq 1,000 \) of registered stem cell donors. Polish and German HF were based on \( n \geq 20,653 \) donors of DKMS Polska [19] and \( n \geq 8,862 \) donors of DKMS Germany [15], respectively. HF data for the four American populations were derived from donors of the National Marrow Donor Program of the United States [21,22]. Sample sizes for these population ranged from \( n = 1,750 \) (Asian/Pacific Americans) to \( n = 7,867 \) (European Americans). More detailed data regarding US populations [23] were not publicly available at the time of data analysis.

The remaining 15 population-specific HF were estimated from minority donors of DKMS Germany [24]. All four sources of HF data [15,19,22,24] tested for deviations from HWE. While some statistically significant deviations from HWE could be identified in three of these studies, their impact on HF estimations was expected to be small.

For each population, we included HF \( \hat{h} \) up to a cumulated frequency of 0.995 with \( \hat{h} \approx h_1 \). Phenotype frequencies that were entered into the model calculations were derived from HF under the assumption of HWE.

Numbers of registered donors were taken primarily from Bone Marrow Donors Worldwide [3] as of February 8, 2012 where available. For the four different American populations, we used figures published on the website of the National Marrow Donor Program of the United States [21]. We then added DKMS minority donors to the respective populations according to their self-assessments and removed them from the German donor file. For the populations “Bosnia-Herzegovina”, “Romania”, and “Kazakhstan”, no donors were included in the BMDW data. Thus, for these populations donor numbers are only due to DKMS minority donors. Donor numbers that were obtained this way are displayed in Table 1. The number of donors was not limited by completeness and resolution of their respective HLA typing as given by the registries, i.e., we did not restrict to donors with certain minimum typing requirements.

Population sizes as of 2011 were taken from the CIA World Factbook [25] for all populations associated with a country. For the four American populations, we used 2010 figures of the US Bureau of census [26]. Table 1 lists the population sizes used for analyses.

Results

We analyzed two sets of populations using our model: The first set included only two different populations (Spanish and German) and was primarily aimed at demonstrating general principles of the analyses. The second example included 21 different populations (see Table 1) and served as first approximation to a real-world scenario. For each example, we discuss the optimal number and composition of new donors with respect to an increase of MP for patients from specific and combined populations.

Calculations for Two Populations

We calculated MP for Spanish and German patients (Figure S3 displayed in File S3, ) and for a combined patient population (Figure 1) as a function of registry size and composition. For the current donor numbers (\( \hat{p}_{\text{Spanish}} = 93,623, \hat{p}_{\text{German}} = 4,343,558 \)), we obtained: \( \hat{p}_{\text{Spanish}} = 0.57, \hat{p}_{\text{German}} = 0.83, \hat{p}_{\text{combined}} = 0.74 \). Without donors from the respective other population, population-specific MP reduced to \( \hat{p}_{\text{Spanish}} = 0.56, \hat{p}_{\text{German}} = 0.8, \hat{p}_{\text{combined}} = 0.74 \). Without consideration of the respective own population, we obtained \( \hat{p}_{\text{Spanish}} = 0, \hat{p}_{\text{German}} = 4,343,558 \). It follows that Spanish patients currently benefit from German donors while German patients do not benefit significantly from Spanish donors. Without consideration of the respective own population, we obtained \( \hat{p}_{\text{German}} = 0, \hat{p}_{\text{combined}} = 0.74 \).

When 500,000 Spanish donors were added to the current registry, the updated MP were \( \hat{p}_{\text{Spanish}} = 0.77, \hat{p}_{\text{German}} = 0.83, \hat{p}_{\text{combined}} = 0.8 \). The addition of 500,000 German donors, on the other hand, led to the following MP: \( \hat{p}_{\text{Spanish}} = 0.56, \hat{p}_{\text{German}} = 0.83, \hat{p}_{\text{combined}} = 0.8 \).
Table 1. Overview on populations included in the analyses.

| Population                | Sample size | # of donors | Population size (in millions) |
|---------------------------|-------------|-------------|-------------------------------|
| African American          | 2,386       | 787,081     | 37.9                         |
| Asian/Pacific American    | 1,750       | 769,846     | 14.6                         |
| Austria                   | 1,698       | 66,014      | 8.4                          |
| Bosnia-Herzegovina        | 1,028       | 1,754       | 3.8                          |
| China                     | 1,282       | 403,945     | 1,336.7                      |
| Croatia                   | 2,057       | 30,823      | 4.4                          |
| European American         | 7,867       | 3,690,624   | 196.9                       |
| France                    | 1,406       | 200,172     | 65.0                         |
| Germany                   | 8,862       | 4,343,558   | 81.5                         |
| Greece                    | 1,894       | 37,760      | 11.3                         |
| Hispanic American         | 1,973       | 1,080,082   | 50.7                         |
| Italy                     | 4,972       | 345,265     | 60.0                         |
| Kazakhstan                | 1,676       | 2,833       | 15.6                         |
| Poland                    | 20,653      | 297,464     | 38.1                         |
| Portugal                  | 1,176       | 283,523     | 10.6                         |
| Romania                   | 1,234       | 2,421       | 21.5                         |
| Russia                    | 4,621       | 16,200      | 142.9                        |
| Spain                     | 1,107       | 93,623      | 47.2                         |
| The Netherlands           | 1,374       | 42,733      | 16.6                         |
| Turkey                    | 33,083      | 114,248     | 73.7                         |
| United Kingdom            | 1,043       | 815,660     | 62.7                         |

Figure 1. MP by registry size and composition for a combined patient population from a registry including Spanish and German donors. The green line indicates the optimal path of donor recruitment.

doi:10.1371/journal.pone.0086605.g001
man = 0.84, pcombined = 0.74. Though existing German donors substantially contributed to current MP of Spanish patients (p = 0.57 with German donors, p = 0.45 without German donors), the addition of 500,000 German donors did not further improve MP of Spanish patients substantially. Generally, MP for Spanish or German patients were most efficiently increased if only Spanish or German donors were recruited, respectively.

With respect to MP of the combined patient population, it was most efficient to only recruit Spanish donors when less than 2.3 million donors were added to the registry. Figure 2 shows, for the case of 500,000 new donors, MP changes by the fraction of Spanish donors. For larger numbers of new registrants, the optimal mix included both Spanish and German donors. For 3,000,000 (5,000,000) new donors, for example, it is optimal to recruit 87.8% (65.1%) Spanish and 12.2% (34.9%) German donors resulting in pcombined = 0.87 (pcombined = 0.89).

Calculations for 21 Populations

We estimated MP for 21 populations and analyzed population-specific MP changes induced by the recruitment of 500,000 donors from the same population (Figure 3). Population-specific MP from same-population donors ranged from 0.08 for Romania to 0.88 for European Americans. For obvious reasons, these MP corresponded strongly with donor numbers by population (Spearman’s rank correlation coefficient, ρ = 0.90). For 4 populations, donor numbers and MP ranks differed by more than 3. MP ranks were lower than donor number ranks for African Americans (ranks 10 and 3, respectively), Italy (ranks 13 and 8) and Turkey (ranks 18 and 12), thus suggesting an especially high intra-population diversity for these populations. The opposite observation was made for the Netherlands (ranks 11 and 15, respectively).

As most populations and the majority of donors included in the model are of European origin, it is not surprising that non-European populations had the smallest increase in their MP due to donors from other populations, namely Asian/Pacific Americans (+0.02), African Americans (+0.02), Hispanic Americans (+0.02) and China (+0.02). The following populations with large donor numbers also showed small MP increases from donors of other populations: Germany (+0.03), European Americans (+0.03) and United Kingdom (+0.04). On the other hand, populations with small donor numbers such as Kazakhstan (+0.58), Bosnia-Herzegovina (+0.55) and Romania (+0.54) benefited most from international donors. As expected, MP that were calculated under consideration of all current donors were less strongly correlated to population-specific donor numbers (Spearman’s rank correlation coefficient, ρ = 0.503).

The largest MP increase by the recruitment of 500,000 new donors from the same population was obtained for Bosnia-Herzegovina (+0.25) followed by Greece (+0.21) and Romania (+0.20). Especially small MP increases were observed for European Americans (+0.004), Germany (+0.006) and Hispanic Americans (+0.01). These populations were among the four populations with the highest MP from the total current registry. For these four populations, the current MP was already larger than 0.8. For the other 17 populations, the number of same-population donors needed to reach 0.8 MP ranged from n = 124,829 for the Netherlands to n = 18,425,025 for Turkey (see Figure S4 in File S4). We also calculated the optimal composition of n = 5,000,000 new donors in order to increase the MP of the combined patient population most efficiently. Due to the very large Chinese population, the result indicated a strong need for additional Chinese donors. The optimal composition of new donors included more than 3.88 million Chinese donors (77.7% of all new donors). Complete results are shown in File S5.

In order to get a more detailed picture of the 20 non-Chinese populations, we also carried out calculations without Chinese donors and patients. Results are displayed in Figure 4. Complete figures are given in File S6. The optimal composition of n = 5,000,000 new donors included donors from 11 populations, with numbers ranging from n = 57,472 (Bosnia-Herzegovina) to n = 1,103,536 (Russia). In that optimal scenario, the smallest MP

Figure 2. Matching probabilities for various patient populations (green: Spanish, red: German, blue: combined) by the share of Spanish donors among n = 500,000 new donors.

doi:10.1371/journal.pone.0086605.g002
increases were observed for Asian/Pacific Americans (+0.003), Hispanic Americans (+0.004) and United Kingdom (+0.01). Spain (+0.19), Romania (+0.18) and Greece (+0.17) had the largest MP increases. The MP of the combined patient population increased from 0.73 to 0.80. As we optimized the MP for a combined patient population, it is not surprising that the optimal composition of new donors did not include individuals from all 20 populations. Apart from population-specific HF and genetic relatedness between various populations, population sizes and population-specific donor numbers are main factors influencing the optimal composition of new donors. It is, therefore, consistent that the optimal composition included, for example, 1.1 million new Russian (population size: 142.9 million, registered donors: 16,200) but no German (population size: 81.5 million, registered donors: 4.3 million) donors.

Patients from populations with new donors in the optimal recruitment scenario benefitted most from recruitment of same-population donors. The MP for Spanish patients, for example, increased from $p_{\text{Spanish}} = 0.64$ to $p_{\text{Spanish}} = 0.83$. If only the $n = 662,283$ new Spanish donors in the optimal recruitment scenario were added to the original registry, the MP increased to $p_{\text{Spanish}} = 0.82$. The addition of the $n = 4,337,717$ non-Spanish donors to the original registry, on the other hand, resulted in $p_{\text{Spanish}} = 0.66$, thus again suggesting a need for same-population donor recruitment.

Sample Size Effects

We analyzed 17 populations with available raw data based on HF derived from two different sample sets: complete samples as given in Table 1 (scenario 1) and random sub-samples with size $n = 1000$ (scenario 2). Results are displayed in Figure 5.

For all populations, the calculated MP from same-population donors (black columns in Figure 5) were higher in scenario 2, thus reflecting the less complete representation of intra-population diversity by smaller samples. MP differences ranged from 0.0004 (Romania) to 0.22 (Italy) and were, as expectable, strongly correlated with sample size differences between both scenarios (Spearman’s rank correlation coefficient, $\rho = 0.919$). In spite of the considerable variation of between-scenario MP differences, MP from same-population donors were highly correlated between both scenarios (Spearman’s rank correlation coefficient, $\rho = 0.951$).

The benefits from international donor exchange (i.e., MP increase by donors from the international registry; grey columns in Figure 5) were higher in Scenario 1 for all populations. This observation results from two factors: overestimation of MP from same-population donors in scenario 2, and larger “overlap” between populations when existing intra-population diversity is better captured by larger samples. The benefits from international donor exchange were strongly correlated between both scenarios (Spearman’s rank correlation coefficient, $\rho = 0.983$).

Regarding MP including international donor exchange (sum of black and grey columns in Figure 5), the combination of the abovementioned sample size effects on MP from same-population donors and on MP increase from the international registry resulted in an MP increase for 5 populations (including Turkey, Poland, Germany and Italy, the four populations with the largest sample sizes) and an MP decrease for 12 populations in Scenario 2 compared to Scenario 1. MP including international donor exchange were well correlated between both scenarios (Spearman’s $\rho = 0.985$) with Italy showing the strongest discrepancy between both scenarios (rank #15 in scenario 1, rank #8 in scenario 2).
Benefits of ongoing domestic recruitment efforts (i.e., MP increase by 500,000 additional donors from the same population; white columns in Figure 5) were higher in Scenario 2 for all populations apart from Germany and China with MP differences ranging from −0.005 (Germany) to 0.19 (Turkey). Benefits of ongoing recruitment were well correlated between both scenarios (Spearman’s rank correlation coefficient, \( r = 0.814 \)). The largest discrepancy could be observed for Turkey (rank #12 in scenario 1, rank #4 in scenario 2).

Figure 6 shows how MP for patients from Turkey, Poland and Germany changed when population-specific HF were derived from smaller sample sizes of \( n = 10,000 \) (analyses for Turkey and Poland only), \( n = 5,000 \), \( n = 2,500 \) and \( n = 1,000 \). For each analysis including 21 populations, all sample sizes apart from the analyzed one remained as given in Table 1.

MP for Polish patients, for example, increased only slightly when the sample size decreased from \( n = 20,653 \) to \( n = 5,000 \): from 0.53 to 0.58 for domestic donors only, from 0.75 to 0.76 for the total donor file including donors from 21 populations, and from 0.78 to 0.80 with 500,000 additional domestic donors. For smaller samples, however, MP for Polish patients were substantially affected by sample size. MP were 0.75, 0.84 and 0.91 in the three respective scenarios with sample size \( n = 1,000 \). MP for German and Turkish patients showed a similar pattern, thus suggesting an only modest dependency of MP from sample size for \( n \geq 5,000 \) while smaller sample sizes showed more relevant impact on calculated MP values.

**Discussion**

In this work, we extended established methods for the estimation of population-specific MP to analyze scenarios including international stem cell donor exchange. We applied our framework to real HF data of up to 21 populations.

As a general result, we consistently observed considerable benefits of intra-population donor recruitment. This is surprising due to the large international registry of more than 21.1 million registered donors and the current level of international exchange (45.8% of all unrelated donations in 2011; [4]).

Our model was based on the assumption that donors who are full HLA matches to patients in need of a transplant will always be identified in the donor search process. There is, however, evidence that fully matching donors may remain unidentified in the donor search process due to incomplete HLA information [27–29]. Possible restrictions of international donor exchange due to socioeconomic, political or other factors were also not considered in our model.

It needs to be emphasized that the model used in this work is focused strictly on patient benefits that were operationalized by the probability to find at least one HLA-matched donor in the global registry for a patient in need of a transplant. The model does not provide any financial cost-benefit estimates of donor recruitment activities carried out in specific countries and/or targeted at defined populations. Among other things, population-specific donor recruitment costs would be required for that purpose.
The nature of our input data led to limitations of our analyses, including: First, the study included about 13 million donors that represent only about 2/3 of the worldwide donor pool.

Second, HF data for 15 of 21 populations included in our calculations were estimated from German minority donors. Though we have previously shown that such HF correspond satisfactorily with HF derived from samples from the respective countries [23,30], this approach is not optimal for several reasons, including: Immigrants to Germany build no random samples of their respective home populations, no information on the regions of origin in the respective home countries is available, and immigrants’ self-assessments of ethnic descent may have substantial error rates that are difficult to quantify.

Third, the optimal definition of populations that enter the analysis is not self-evident. Regional HLA frequency differences have been described for several countries [31–35]. Nevertheless, it may not be useful to define populations too narrow as corresponding sample sizes will decrease and related problems will aggravate. On the other hand, the country-based definition of populations as used for the 17 non-US populations in our calculations may be oversimplifying at least for countries with heterogeneous population structure as, for example, China [36,37] or Turkey. Further, the four US populations are not well-defined. For instance, it has been shown [38] that Eastern European American donors genetically differ from Western European American donors.

Fourth, we used the numbers of registered donors by population for modeling the current registry, thus neglecting issues of donor availability. In principle, this problem can easily be resolved by introducing a factor describing donor availability. As donor availability rates differ between various populations [39], this factor is required to be population-specific. In our setting, it has not been included as availability data based on a sufficient number of typing requests were not available for all populations.

Fifth, calculations regarding MP of combined patient populations were based on the assumption that patients from all populations have same access to unrelated HSCT when MP issues are not considered. It is, however, known that, in practice, the number of patients from a specific population for whom a donor is searched depends on various factors including population size, population-specific disease incidences, and socioeconomic parameters [40].

Sixth, most HF used for calculations were based on samples of sizes between $n = 1000$ and $n = 5000$ while our results suggest that estimated MP values may strongly deviate from “real” values for $n < 3000$. Future studies should nevertheless aim at a larger and more homogeneous input data for HF estimate with respect to sample sizes. Further, there is evidence that expectation-maximization algorithms which are used to compute HF do not perform well not only when the input sample size is small but also in cases of high polymorphism (as for HLA) and when distant loci (such as, for example, HLA-A and HLA-DRB1) are included [41].

Seventh, we assumed that donor and patient HF are identical for each population, thus neglecting potential HLA associations with diseases that may be treated by stem cell transplantation.
Eighth, of the 84 population-locus combinations that entered the analyses of our study, 12 showed deviations from HWE that were statistically significant [15,19,22,24]. In 10 of these cases, deviations from HWE were associated with excess homozygosity. It has been shown that deviations from HWE do not affect the accuracy of HF estimations with the EM algorithm negatively in these cases [42]. In one case (HLA-DR for Poland), the $p$ value of the test for deviation from HWE was 0.011, thus not indicating a quantitatively relevant deviation from HWE [13]. The remaining combination with significant deviation from HWE (HLA-A for European American) showed both a small $p$ value ($<10^{-4}$) and excess heterozygosity. Though the relatively large size of the underlying sample ($n=7,867$) may have contributed to the small $p$ value, this deviation from HWE creates a potential source of error.

Ninth, new HLA alleles are identified at an increasing rate [43,44]. Carriers of yet unassigned alleles were excluded from HF estimation in some underlying studies [15,19,24]. This approach causes an error that is difficult to quantify. It should, however, be small compared to most other errors given above.

Based on the considerable limitations described above, one may argue that analyses as those presented in this work are premature and should be postponed until better input data and especially 4-locus high-resolution HF data based on larger samples are available. As there are, however, substantial current donor recruitment efforts in an increasing number of countries in order to meet the needs of patients without HLA-identical family donor, this argument may be not appropriate.

Besides, key results of our analyses are sufficiently robust to be valid despite model and input data restrictions: First, we consistently found strong benefits of same-population donor recruitment for population-specific MP. In spite of the extensive current cross-border stem cell donor exchange, our data suggest that further substantial MP increases may be difficult to achieve without domestic donor recruitment for many populations. This observation is in accordance with previous results regarding Polish and German donor and patient populations [19]. We therefore recommend to critically re-assess national strategies that neglect domestic donor recruitment, especially if only few donors have been recruited so far. Second, though MP values depended considerably on sample sizes, the ranking of populations with respect to current MP and MP increases from future recruitment efforts remained relatively stable in scenarios that were based on different sample sizes. This observation suggests that our model is suited to identify populations with a specific need for donor recruitment efforts.

We concede, however, that it is doubtful if any prioritization of recruitment efforts by donor population that results from model calculations with the current input data limitations is more

**Figure 6. Population-specific MP for German, Polish and Turkish patients based on HF derived from various sample sizes as shown at the x-axis.** Black, grey and white columns are defined as in Figure 3. doi:10.1371/journal.pone.0086605.g006
precise than a prioritization that is semi-quantitatively derived from basic parameters as, for example, current donor numbers or intra-population diversity. The results presented here should, therefore, be understood rather as a step to the enabling of a rational global stem cell donor recruitment strategy than as a final result. Though HP may also be estimated from incomplete data [23,45,46], it would be most helpful for the ongoing refinement of input data to type future new registrants “completely”, i.e., at least for the HLA loci A, B, C and DRB1 at high resolution. This strategy has also been identified as beneficial for donor registry operations [47]. Cost barriers to this approach should increasingly diminish due to the use of next-generation sequencing technologies for high-throughput donor HLA typing [48].

**Summary**

Summarized, we extended established methods for MP estimation and built a model intended to estimate the need for and impact of stem cell donor recruitment efforts in various populations in a setting of international donor exchange. In spite of considerable limitations due to the nature of our input data, we could identify a need for domestic donor recruitment efforts for populations without large existing donor base as a general result. The availability of larger samples of completely typed donors will allow substantial refinements of the model calculations.

**Supporting Information**

File S1 Some mathematical properties of the scalar field $p_k$. (DOC)

**References**

1. Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357: 1472-1475.
2. Gratzow A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, et al. (2010) Hematopoietic stem cell transplantation: A global perspective. JAMA 303: 1617–1624.
3. Bone Marrow Donors Worldwide. Available: http://www.bmdw.org. Accessed 4 June, 2013.
4. World Marrow Donor Association. Annual Report 2011.
5. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, et al. (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110: 4576–4583.
6. Bray RA, Hurley CK, Kamani NR, Woolfrey A, Moller C, et al. (2008) National Marrow Donor Program HLA matching guidelines for unrelated adult hematopoietic cell transplants. Biol Blood Marrow Transplant 14: 45–53.
7. Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA (2010) The impact of HLA genotyping on survival following unrelated donor hematopoietic stem cell transplantation. Br J Haematol 150: 251–258.
8. Spellman SR, Eapen M, Logan BR, Mueller C, Rabinstein P, et al. (2012) A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood 120: 259–263.
9. Hwang WY, Ong SY (2009) Allogeneic hematopoietic stem cell transplantation without a matched sibling donor: current options and future potential. Ann Acad Med Singapore 38(4): 346–355.
10. Tu B, Cha N, Yang R, Ng J, Hurley CK (2013). A one-step DNA sequencing strategy to HLA type hematopoietic stem cells at donor recruitment - rethinking typing strategies. Tissue Antigens 81(3): 150–160.
11. Sommenberg FA, Eckman MH, Pauker SG (1989) Bone marrow donor registries: the relation between registry size and probability of finding complete and partial matches. Blood 74: 2560–2578.
12. Beatty PG, Mori M, Milford E (1995) Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60: 778–783.
13. Muller CR, Ehninger G, Goldmann SF (2003) Gene and haplotype frequencies for the loci HLA-A, HLA-B, and HLA-DR based on over 13,000 German blood donors. Hum Immunol 64: 137–151.
14. Kollman C, Abella E, Beatty RL, Beatty PG, Chakraborty R, et al. (2004) Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. Transplantation 78: 89–93.
15. Schmid AH, Bailer D, Solloch UV, Stahr A, Cereb N, et al. (2009) Estimation of high-resolution HLA-A, -B, -C - DRB1 allele and haplotype frequencies based on 1992 German stem cell donors and implications for strategic donor registry planning. Hum Immunol 70: 895–902.
16. Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12: 921–927.
17. Excoffier L, Laval G, Schneider S (2005) Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evolutionary Bioinformatics Online 1: 47–50.
18. Delan J, Buck K, Yang SY, Schmidt AH, Hartzmann R, et al. (2011) B/L high-resolution HLA match rate: the impact of race. Biol Blood Marrow Transplant 17: S170–S171 (Abstract).
19. Schmid AH, Solloch UV, Piegel J, Baier D, Bohme I, et al. (2011) High-resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,633 stem cell donors. Hum Immunol 72: 558–565.
20. Bergstrom TC, Garratt RJ, Sheehan-Conor D (2009) One chance in a million: Altruism and the bone marrow registry. American Economic Review 99: 1309–1334.
21. National Marrow Donor Program. Available: http://bioinformatics.nmdp.org/HLA/Haplotypes_Frequencies/High_Resolution_HLA_Altles_US_Pop/High-Resolution_HLA_Altles_and_Haplotypes_in_the_US_Population.aspx. Accessed 19 March 2012.
22. Maier S, Graget I, Kitz W (2007) High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 68: 779–788.
23. Graget I, Madbouly A, Freeman J, Maiers M (2007) Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol 74(10): 1313–1320.
24. Pangel J, Solloch UV, Hofmann JA, Lange V, Ehninger G, et al. (2013) High-resolution HLA haplotype frequencies of stem cell donors in Germany with foreign parentage: How can they be used to improve unrelated donor searches? Hum Immunol 74: 339–340.
25. CIA World Factbook. Available: https://www.cia.gov/library/publications/the-world-factbook/index.html. Accessed 19 March 2012.
26. United States Census Bureau. Available: http://factfinder2.census.gov/faces/nav/jsf/pages/index.xhtml. Accessed 19 March 2012.
27. Confer DL (2001) The National Marrow Donor Program: Meeting the needs of the medically underserved. Cancer 91: 274–278.
28. Schmidt AH, Solloch UV, Baier D, Grathwohl A, Hofmann JA, et al. (2011) Support of unrelated stem cell donor searches by donor-center-initiated HLA typing of potentially matching donors. PLoS One 6: e20268.

29. Schmidt AH, Solloch U, Sauter J, Hofmann JA, Pingel J, et al. (2013) Simulation shows that registered stem cell donors with full donor-patient HLA-match can remain unidentified. Tissue Antigens 81: 270 (Abstract).

30. Schmidt AH, Solloch UV, Baier D, Yazici B, Ozcan M, et al. (2009) Criteria for initiation and evaluation of minority donor programs and application to the example of donors of Turkish descent in Germany. Bone Marrow Transplant 44: 405–412.

31. Lonjou C, Clayton J, Cambon-Thomsen A, Raffoux C (1995) HLA-A, -B, -DR haplotype frequencies in France - implications for recruitment of potential stem cell donors. Transplantation 60: 375–383.

32. Rendine S, Borelli I, Barbanti M, Sacchi N, Roggero S, et al. (1998) HLA polymorphisms in Italian bone marrow donors: a regional analysis. Tissue Antigens 52: 135–146.

33. Schmidt AH, Solloch UV, Baier D, Yazici B, Ozcan M, et al. (2009) Criteria for initiation and evaluation of minority donor programs and application to the example of donors of Turkish descent in Germany. Bone Marrow Transplant 44: 405–412.

34. Buhler S, Nunes JM, Nicoloso G, Tiercy JM, Sanchez-Mazas A (2012) The heterogeneous HLA genetic makeup of the Swiss population. PLoS One 7: e41400.

35. Schmidt AH, Solloch UV, Baier D, Pingel J, Boehme I et al. (2013) Regional HLA Differences in Poland and Their Effect on Stem Cell Donor Registry Planning. PLoS One 8: e73835.

36. Shen CM, Zhu BF, Deng YJ, Ye SH, Yan JW, et al. (2010) Allele polymorphism and haplotype diversity of HLA-A, -B, and -DRB1 loci in sequence-based typing for Chinese Uyghur ethnic group. PLoS One 5: e13458.

37. Qin Qin P, Su F, Xiao Yan W, Xing Z, Meng P, et al. (2011) Distribution of human leukocyte antigen-A, -B and -DR alleles and haplotypes at high resolution in the population from Jiangsu province of China. Int J Immunogenet 38: 475–481.

38. Mack SJ, Tu B, Lazarro A, Yang R, Lancaster AK, et al. (2008) HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population. Tissue Antigens 73: 17–32.

39. Switzer GE, Bruce JG, Myaskovsky L, DiMartini A, Shellman D, et al. (2013) Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood 121(8): 1469–76.

40. Grathwohl A, Baldomero H, Frauenfelder K, Urbano-Ispizua A, Diederwieser D (2007) Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 39: 71–87.

41. Castelli EC, Mendes-Junior CT, Veiga-Castell LC, Pevira NF, Petzl-Erler ML, et al. (2010) Evaluation of computational methods for the reconstruction of HLA haplotypes. Tissue Antigens 76: 459–466.

42. Fallin D, Schork NJ (2000) Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet. 67(4): 947–59.

43. Lazaro AM, Xiao Y, Masaberg C, Tu B, Ng J, et al. (2011) Seventy-eight novel HLA class I and II alleles identified during routine registry typing in 2008 and 2009. Tissue Antigens 77(1): 54–61.

44. Robinson J, Hallismell JA, McWilliam H, Lopez R, Parham P, et al. (2013) The IMGT/HLA Database. Nucleic Acids Research 41: D1222–7.

45. Kollman C, Maiers M, Gragert I, Muller C, Setterholm M, et al. (2007) Estimation of HLA-A, -B, -DRB1 haplotype frequencies using mixed resolution data from a national registry with selective retyping of volunteers. Hum Immunol 68: 950–958.

46. Eberhard HP, Feldmann U, Bochtler W, Baier D, Kurt C, et al. (2010) Estimating unbiased haplotype frequencies from stem cell donor samples typed at heterogeneous resolutions: a practical study based on over 1 million German donors. Tissue Antigens 76: 352–361.

47. Muller CR, Feldmann U, Bochtler W, Morsch S, Schmidt AH (2012) The effect of age, gender and typing resolution on the probability of stem cell donation. Hum Immunol 73: 121 (Abstract).

48. Lange V, Boehme I, Hofmann J, Lang K, Sauter J, et al. (2014) Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing. BMC Genomics 15:63.